Refractory or resistant carcinoid disease and acromegaly
Showing 1 - 25 of >10,000
Steroid Resistant Acute GVHD Trial in Lyon (inolimomab)
Available
- Steroid Resistant Acute Graft Versus Host Disease
- inolimomab
-
Lyon, FranceElsaLys Biotech
Sep 16, 2021
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma Refractory
Active, not recruiting
- Castration Levels of Testosterone
- +9 more
- Recombinant EphB4-HSA Fusion Protein
-
Los Angeles, California
- +2 more
Apr 4, 2022
Germ Cell Tumors, Measurable Disease Trial in Milano (Pazopanib)
Completed
- Germ Cell Tumors
- Measurable Disease
-
Milano, Mi, ItalyFondazione IRCCS Istituto Nazionale dei Tumori
May 12, 2021
Chronic Myeloid Leukemia in Chronic Phase Trial in Belgium, Germany (LBH589)
Terminated
- Chronic Myeloid Leukemia in Chronic Phase
-
Bruxelles, Belgium
- +9 more
Jul 14, 2021
Metastatic Castration Resistant Prostate Cancer Trial in United States (LAVA-1207)
Recruiting
- Metastatic Castration Resistant Prostate Cancer
- LAVA-1207
-
Tampa, Florida
- +3 more
Nov 18, 2022
Movement Disorders Trial in Beijing (MRgFUS treatment)
Not yet recruiting
- Movement Disorders
- MRgFUS treatment
-
Beijing, ChinaChinese PLA General Hospital
Nov 17, 2022
Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer, Fallopian Tube Cancer Trial in Orlando, Albuquerque
Recruiting
- Platinum-resistant Ovarian Cancer
- +6 more
- olvimulogene nanivacirepvec
- +3 more
-
Orlando, FloridaAdventHealth Cancer Institute
Sep 1, 2022
Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer Trial in New Haven, Baltimore (Ixabepilone,
Active, not recruiting
- Epithelial Ovarian Cancer
- +2 more
-
New Haven, Connecticut
- +1 more
Jan 11, 2023
Locally Advanced Neuroendocrine Tumor, Metastatic Neuroendocrine Tumor Trial in Houston (Placebo Administration, Questionnaire
Recruiting
- Locally Advanced Neuroendocrine Neoplasm
- Metastatic Neuroendocrine Neoplasm
- Placebo Administration
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Jan 31, 2023
Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal
Completed
- Platinum-Resistant Fallopian Tube Carcinoma
- +8 more
- Bevacizumab
- Irinotecan Sucrosofate
-
Chicago, IllinoisNorthwestern University
Dec 21, 2022
Prostate Cancer Patients Trial in Qingdao, Shanghai (Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin)
Recruiting
- Prostate Cancer Patients
- Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin
-
Qingdao, Shandong, China
- +1 more
May 3, 2022
Carcinoid Tumor Trial in Boston (Ziv-aflibercept)
Active, not recruiting
- Carcinoid Tumor
-
Boston, Massachusetts
- +2 more
Oct 14, 2022
Acute GVHD in Intestine, Steroid Refractory GVHD Trial in France, Germany, Spain (MaaT013)
Recruiting
- Acute Graft Versus Host Disease in Intestine
- Steroid Refractory GVHD
-
Amiens, France
- +17 more
Jun 20, 2022
Acute GVHD in Intestine, Steroid Refractory GVHD Trial in France (MaaT013)
Available
- Acute Graft Versus Host Disease in Intestine
- Steroid Refractory GVHD
-
Amiens, France
- +19 more
Jun 20, 2022
Graft-versus-host Disease, Poor Graft Function, Low Donor T-cell Chimerism Trial in Belgium, Netherlands (Mesenchymal stem
Recruiting
- Graft-versus-host Disease
- +2 more
- Mesenchymal stem cells
-
Edeghem, Antwerpen, Belgium
- +11 more
Sep 19, 2022
Ovarian Cancer, Relapsed or Refractory, Chiauranib Trial in Shanghai (chiauranib, Placebo, Paclitaxel)
Recruiting
- Ovarian Cancer
- +3 more
- chiauranib
- +2 more
-
Shanghai, ChinaFudan University Shanghai Cancer Center
Mar 7, 2022
Safety and Efficacy Trial in Suzhou (Basiliximab, Vedolizumab)
Recruiting
- Safety and Efficacy
-
Suzhou, Jiangsu, ChinaThe First Affiliated Hospital of Soochow University
Sep 27, 2023